Your Article Summary
See Latest ArticlesNeurological outcome of long-term glioblastoma survivors
Journal of Neuro-Oncology, 06/30/09
Hottinger AF et al. - Treatment-related complications occurred a median of 2.7 years from diagnosis. Long-term survivors remain rare, but are found across all age groups despite multiple recurrences; clinically significant delayed complications of treatment are common.
Related Articles
Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme
Journal of Neuro-Oncology, 10/28/09
Relevance Score: 88%
Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment
Clinical Cancer Research, 10/01/09
Relevance Score: 88%
Multiple extracranial metastases from secondary glioblastoma multiforme: a case report and review of the literature
Journal of Neuro-Oncology, 11/18/09
Relevance Score: 87%
Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression
Clinical Cancer Research, 10/06/09
Relevance Score: 87%
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme
Journal of Neuro-Oncology, 10/01/09
Relevance Score: 87%
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A heritable predisposition to pituitary tumors
Pituitary, 12/18/09
Temozolomide (Temodar) and capecitabine (Xeloda) treatment of an aggressive corticotroph pituitary tumor
Pituitary, 12/18/09
Complete percutaneous treatment of vertebral body tumors causing spinal canal compromise using a transpedicular cavitation, cement augmentation, and radiosurgical technique
Neurosurgical Focus, 12/18/09